March 5, 2019
Otsuka Pharmaceutical Co., Ltd.
H. Lundbeck A/S
Selincro Tablets 10mg Launched in Japan
First Drug Approved in Japan to Reduce Alcohol Consumption in Alcohol-dependent Patients
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A / S of Denmark are pleased to announce that Otsuka has launched Selincro Tablets 10mg (generic name: nalmefene hydrochloride), a therapeutic drug treatment to reduce alcohol consumption in alcohol-dependent patients in Japan.
Selincro, the first dual-acting opioid system modulator in Japan, acts on the brain's motivational system, which is dysregulated in patients with alcohol dependence. In 2013 Otsuka formed an agreement with Lundbeck on the development and commercialization in Japan of Lundbeck's Selinclo.
Information in this news release was current as of the original release date.